Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Unity Biotechnology in a note issued to investors on Tuesday, April 16th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($2.42) per share for the year, up from their previous estimate of ($3.83). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.96) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2025 earnings at ($2.52) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($0.29) EPS.
Unity Biotechnology Trading Down 0.7 %
Shares of NASDAQ:UBX opened at $1.50 on Thursday. The firm has a 50 day moving average of $1.65 and a 200-day moving average of $1.77. The stock has a market capitalization of $25.19 million, a PE ratio of -0.51 and a beta of 0.87. Unity Biotechnology has a 12 month low of $1.50 and a 12 month high of $3.82.
Hedge Funds Weigh In On Unity Biotechnology
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
Read More
- Five stocks we like better than Unity Biotechnology
- What is the Dow Jones Industrial Average (DJIA)?
- Comprehensive Analysis of PayPal Stock
- Insider Trading – What You Need to Know
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- 3 Fintech Stocks With Good 2021 Prospects
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.